Last reviewed · How we verify

DFDBA with atorvastatin

Kamineni Institute of Dental Sciences · FDA-approved active Small molecule

DFDBA (demineralized freeze-dried bone allograft) combined with atorvastatin promotes bone regeneration and reduces inflammation in periodontal and dental defects.

DFDBA (demineralized freeze-dried bone allograft) combined with atorvastatin promotes bone regeneration and reduces inflammation in periodontal and dental defects. Used for Periodontal bone defects and regeneration, Alveolar bone loss associated with periodontitis, Dental implant site augmentation.

At a glance

Generic nameDFDBA with atorvastatin
Also known asatorvastatin gel
SponsorKamineni Institute of Dental Sciences
Drug classBone graft material with adjunctive pharmaceutical agent
ModalitySmall molecule
Therapeutic areaDentistry / Periodontics / Oral Surgery
PhaseFDA-approved

Mechanism of action

DFDBA is an allograft material that provides a scaffold for bone formation and contains osteoinductive proteins that stimulate new bone growth. Atorvastatin, a statin, enhances osteoblast differentiation and bone formation while reducing inflammatory markers, synergistically improving bone regeneration outcomes in dental applications.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: